Groups for patients with rare diseases have mixed feelings about Big Pharma: We explore how pharma marketers can better support patients who have uncommon medical conditions.
GLP-1s found to reduce the risk of diabetes: Lilly and Novo want the medical community to know that their blockbuster drugs work best when used over a long time.
MA plans score higher than commercial insurance on customer satisfaction: MA insurers that prioritize aspects of the customer experience seniors value the most will maintain their competitive edge.
Employer healthcare costs will surge at the highest rate in 15 years: Pharma spending is the biggest driver. We examine cost-cutting strategies employers might implement.
Sesame rolls out weight loss program offering compounded GLP-1s: Sesame has a limited window of time to extract maximum revenue from the program as competitors race to meet demand for GLP-1s amid drug shortages.
LetsGetChecked set to acquire Truepill: Under one umbrella, the combined company can expand its services to its broader user base—making it a force to be reckoned with in the at-home diagnostic testing space.
Walgreens expands clinical trials with $100M government deal: We explore why Walgreens is expanding its clinical trials division while CVS is shutting down its division.
Doctors’ media consumption habits are shifting: They’re using social media, podcasts, and video games for professional purposes. We explore what it all means for pharma marketers.
US adults are using AI chatbots to find health information: Despite concerns about their accuracy, consumers keep returning to the AI tools. Healthcare and pharma marketers have an opportunity to market through them.
Kaiser Permanente rolls out Abridge’s genAI clinical documentation tool: Here’s why improvements to genAI are needed for most healthcare use-cases—but not clinical documentation.
Mark Cuban Cost Plus Drug Co. will publish customer contracts online: Here’s how the PBM disruptor’s bid to further advance prescription drug price transparency is a sign of things to come in the space.
Healthcare, pharma ramp-up partnerships with social media influencers: We explore the factors driving brands to embrace health influencers and examine how marketers can better navigate the creator economy.
Ro rolls out GLP-1 insurance coverage checker: The tool will help consumers determine if their health plan will cover weight loss drugs, while Ro could drum up enrollment in its own weight loss program.
Google’s new smartwatch will have a loss-of-pulse detector: We explore if the health-tracking capability can prove effective.
CMS unveils final prices of 10 drugs negotiated under the IRA: Here’s why drugmakers aren’t too concerned about the perceived impact on their bottom lines.
Some consumers lack trust in prescription drugs and vaccines: Here’s how pharma marketers can get skeptics to consider using their treatments.
23andMe launches telehealth program for GLP-1s: We think 23andMe is entering the game too late to fully realize its GLP-1 ambitions.
Stryker to acquire careAI, developer of ambient intelligence solutions: The acquisition signals Stryker is laying the groundwork for the future of its hospital business. Here’s why.
Consumer trust in doctors and hospitals is plummeting: We explore what’s driving the decline and how healthcare providers and marketers can rebuild trust with patients.
BCBS Tennessee rolls out healthy meal program: We examine why the partnership could be a winning strategy for health insurers and patients.